NOSOTROS:
Novartis Skip to main navigation Skip to main content Skip to Footer Google Tag Manager Navigate NovartisPatients Healthcare Professionals Media Investors Partners ESG Job Seekers Clinical Trials Coronavirus GlobalNovartis site directory Our CompanyOur LeadershipBoard of Directors Executive Committee of Novartis Our ApproachStrategy Corporate Responsibility Diversity & Inclusion Partnering Culture and Values Our BusinessGlobal Product Portfolio Innovative Medicines Novartis Pharmaceuticals Novartis Gene Therapies Novartis Oncology Sandoz MediaNewsroom News Archive Multimedia Resources Subscribe to Updates InvestorsEvent Calendar Financial Data Share Data & Analysis Shareholder Information Environmental, Social & Governance Our FocusDisease AreasCancer Cardiovascular, Renal & Metabolism Immunology & Dermatology Ophthalmology Neuroscience Respiratory Platforms and TechnologyData and Digital Cell & Gene Therapy Novartis StoriesDiscovery From Our Labs Access to Healthcare Patient Perspectives People and Culture Live Magazine Our ImpactBuilding Trust with SocietyCorporate Responsibility Ethical Standards Access Environmental Sustainability Global HealthMalaria Sickle Cell Disease Chagas disease Leprosy Novartis Foundation ESG Performance and ReportingMateriality Environment, Social and Governance Transparency and Disclosures Positions on Key Topics Statements on Key Issues Our ScienceResearch & Early DevelopmentNovartis Institutes for BioMedical Research Research Disease Areas Postdoc Program Open Source Science Drug Development at NovartisNovartis Pipeline Clinical Trials Translational Medicine Global Product Portfolio Science StoriesDiscovery From Our Labs CareersYour CareerNovartis Career Search Novartis Teams and Skills Working at NovartisDiversity & Inclusion Culture and Values Corporate Responsibility Career ProgramsOur Career Programs Students and Scholars Novartis Quantitative Sciences Hackathon SearchNovartis Home At Novartis, we are reimagining medicine Opens a Dialog World Sight Day 2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
Learn More 1_azwfmd33 Life Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
Learn More Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Enter Cell & Gene Therapy Explained
What if medicine for certain diseases only needed to be taken once?
Learn More 1_4y4ere9u Our people, our stories, our culture on @novartislife Instagram
Find out more about our Inspired, Curious and Unbossed culture as we celebrate our people who are reimagining medicine and their stories on our new community channel @novartislife.
Learn MoreLatest News Oct 21, 2020 Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
Oct 16, 2020 Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
Oct 09, 2020 Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
Oct 05, 2020 New Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
Media releases Novartis on Twitter @Novartis 8 hours 31 min ago
Congratulations to Novartis Oncology President Susanne Schaffert for being named by @FortuneMPW as one of the Most… https://t.co/4h88KeZOpg @Novartis 1 day 6 hours ago
This week, Dominic De Souza, Global Head of Anti-Infectives, Sustainability and #AMR program at @Sandoz_Global join… https://t.co/hqywTyGRra @Novartis 3 days 12 hours ago
DNA is the foundation of our genetic make-up. But sometimes there’s an error in the blueprint that leads to disease… https://t.co/6S0RDXEXBl
Follow Us AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
Learn More Our commitment to doing what's right
Novartis is committed to ensuring our associates are empowered to do what’s right. On September 01, 2020, we introduced a new Code of Ethics for Novartis.
Learn More World Heart Day 2020: From our heart to yours
For the past six decades, Novartis has been working to advance heart health around the world.
Learn More Novartis GlobalNavigate NovartisPatients & CaregiversHealthcare Professionals Investors Media Society & ESG Partners Contact UsGlobal ContactsOffice LocationsFor InvestorsFor MediaAbout NovartisOur CompanyOur FocusOur ImpactOur ScienceOur StoriesOur PortfolioGlobal Product PortfolioGlobal Clinical PipelineCareersCareer Search Connect with Novartistwitter linkedin youtube facebook instagram Novartis Site Directory © 2020 Novartis AG Terms of Use Privacy Policy Contact Us Site Map
This site is intended for a global audience.
